选择性COX-2抑制剂用于术后疼痛管理的多维评估:随机对照试验的系统综述与Meta分析
该系统综述与Meta分析纳入38项随机对照试验共5424例成人患者,评估围术期选择性COX-2抑制剂对术后急性疼痛等多维结局的影响。结果显示选择性COX-2抑制剂可能临床意义地减少急性疼痛对日常功能的干扰,并可能改善慢性疼痛发生率和恢复质量,但证据确定性多为低至中等。
要点
- 围术期选择性COX-2抑制剂可能临床意义地减少急性疼痛对日常功能的干扰(Brief Pain Inventory均差-1.1)。
- 可能降低慢性疼痛发生率(OR 0.44),但对慢性疼痛强度无显著影响。
- 可能改善恢复质量(QoR-9均差0.84),且不增加其他不良事件。
核心结论
- 围术期选择性COX-2抑制剂可能临床意义地减少急性疼痛对日常功能的干扰,并可能改善慢性疼痛发生率和恢复质量。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase和Cochrane CENTRAL,纳入38项随机对照试验共5424例成人患者,比较全身围术期选择性COX-2抑制剂与安慰剂、阿片类药物或常规护理。
主要发现
- 选择性COX-2抑制剂与急性疼痛相关干扰减少相关(Brief Pain Inventory均差-1.1,95%CI -1.4至-0.8,n=7,中等确定性)。
- 选择性COX-2抑制剂与慢性疼痛发生率降低相关(OR 0.44,95%CI 0.21至0.93,n=5,低确定性)。
- 对慢性疼痛强度无显著影响(均差-1.0,95%CI -2.7至0.7,n=1,极低确定性)。
- 恢复质量改善(QoR-9均差0.84,95%CI 0.33至1.35,n=7,低确定性)。
- 术中失血量减少(均差-22 ml,95%CI -40至-4,n=3,低确定性),其他不良事件无差异。
关键数值与推荐
- 主要结局为术后1个月内采用任何经验证的多维工具评估的急性疼痛相关日常活动干扰,Brief Pain Inventory量表0-10分,最小临床重要差异为1.0。
- 临床意义通过估计组间达到最小重要差异的参与者比例差异来评估,模型化风险差异显示COX-2抑制剂对急性疼痛有显著获益。
临床怎么用
- 围术期可考虑使用选择性COX-2抑制剂以减轻急性疼痛对日常功能的干扰并改善恢复质量。
- 使用选择性COX-2抑制剂可能降低慢性疼痛发生率,但需注意证据确定性多为低至中等。
- 选择性COX-2抑制剂未增加急性肾衰竭、胃肠道出血、骨愈合受损、心肌梗死、卒中或死亡等不良事件。
局限性
- 部分结局证据确定性低或极低,如慢性疼痛强度和恢复质量。
- 慢性疼痛强度分析仅基于1项研究(n=1)。
- 术中失血量分析仅基于3项研究(n=3),证据确定性低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although selective cyclooxygenase-2 (COX‑2) inhibitors are commonly used in perioperative pain management, it is uncertain whether these anti-inflammatory agents meaningfully improve postoperative recovery, including the impact of pain on daily functioning. METHODS: This study systematically searched MEDLINE, Embase, and Cochrane CENTRAL for randomized controlled trials comparing systemic perioperative selective COX‑2 inhibitors with placebo, opioids, or usual care in adults. The primary outcome was postoperative acute pain, assessed using any validated multidimensional instrument evaluating pain‑related interference with daily living ( e.g. , Brief Pain Inventory; 0 to 10 scale, minimal clinically important difference = 1.0) within 1 month after surgery. Secondary outcomes included chronic pain, quality of recovery, and adverse events. Two reviewers independently performed study selection, data abstraction, risk of bias and certainty of evidence assessments. Clinical significance was assessed by estimating the difference between groups in the proportion of participants achieving the minimal important difference. RESULTS: A total of 9,071 citations were screened, and 38 randomized controlled trials (5,424 participants) met eligibility criteria. Selective COX-2 inhibitors were associated with a reduction in acute pain‑related interference (Brief Pain Inventory mean difference [MD], -1.1; 95% CI, -1.4 to -0.8; n = 7; moderate certainty) and in chronic pain incidence (odds ratio, 0.44; 95% CI, 0.21 to 0.93; n = 5; low certainty), but no significant effect was found on chronic pain intensity (MD, -1.0; 95% CI, -2.7 to 0.7; n = 1; very low certainty). The modeled risk difference for achieving a clinically important analgesic effect showed a substantial benefit of COX-2 inhibitors for acute pain. Quality of recovery improved with the intervention (Quality of Recovery-9 [0 to 18 scale] MD, 0.84; 95% CI, 0.33 to 1.35; n = 7; low certainty). Intraoperative blood loss was lower (MD, -22 ml; 95% CI, -40 to -4; n = 3; low certainty), and no differences were observed in other adverse events ( i.e. , acute renal failure, gastrointestinal bleeding, impaired bone healing, myocardial infarction, stroke, and death). CONCLUSIONS: Perioperative selective COX‑2 inhibitors likely provide a clinically meaningful reduction in acute pain - related interference with daily function and may improve chronic pain and quality of recovery.
引用
- Kahloon U, Le JBP, Tierney S, et al. Effectiveness of Selective Cyclooxygenase-2 Inhibitors for Postoperative Pain Management Using Multidimensional Pain Assessment: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Anesthesiology. 2026. PMID: 42708838. doi:10.1097/ALN.0000000000006216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。